Abeona Therapeutics Inc (ABEO)

Currency in USD
5.9200
-0.1200(-1.99%)
Closed·
5.9700+0.0500(+0.84%)
·
ABEO is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
5.88006.0350
52 wk Range
4.00007.6500
Key Statistics
Prev. Close
6.04
Open
5.99
Day's Range
5.88-6.035
52 wk Range
4-7.65
Volume
912.89K
Average Volume (3m)
1.37M
1-Year Change
-13.3236%
Book Value / Share
2.25
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ABEO Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
18.8571
Upside
+218.53%
Members' Sentiments
Bearish
Bullish
ProTips
Analysts anticipate sales growth in the current year

Abeona Therapeutics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell

Analyst Ratings

6 Buy
0 Hold
0 Sell
Ratings:
6 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 18.8571
(+218.53% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Oppenheimer
Buy21.00+254.73%22.00MaintainAug 14, 2026
Oppenheimer
Buy22.00+271.62%-MaintainMar 17, 2026
Stifel
Buy17.00+187.16%19.00MaintainMar 17, 2026
Oppenheimer
Buy22.00+271.62%19.00MaintainMar 09, 2026
Cantor Fitzgerald
Buy28.00+372.97%-MaintainJan 15, 2026

Abeona Therapeutics Inc Earnings Call Summary for Q2/2026

  • ZEVASKYN Q2 revenue reached $11.4M, up 31% sequentially but missed $12.24M estimate; shares dropped 10.99% to $6.64 in premarket trading.
  • Net loss widened to $20.2M ($0.35/share) from Q1's $17.1M as company scaled commercial operations and treatment center network to 7 sites.
  • Manufacturing issues prevented revenue recognition for 2 of 5 treated patients; gross margin at 63% vs. long-term target of 85-90% at full capacity.
  • CMS granted ZEVASKYN New Technology Add-on Payment status for fiscal 2027, expected to improve hospital reimbursement for Medicare patients.
  • Company ended quarter with $146.8M cash; no formal guidance issued but management targets steady treatment cadence with 40% patient population access.
Last Updated: 2026-08-13, 09:42 a/m
Read Full Transcript

Earnings

Latest Release
Aug 13, 2026
EPS / Forecast
-0.35 / -0.22
Revenue / Forecast
11.38M / 12.24M
EPS Revisions
Last 90 days

ABEO Income Statement

Compare ABEO to Peers and Sector

Metrics to compare
ABEO
Peers
Sector
Relationship
P/E Ratio
−5.4x5.5x−0.4x
PEG Ratio
0.02−0.230.00
Price/Book
2.6x2.8x2.6x
Price / LTM Sales
13.3x7.3x3.1x
Upside (Analyst Target)
187.2%129.0%48.1%
Fair Value Upside
Unlock16.2%6.3%Unlock

Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States. It develops ZEVASKYN, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 to treat autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was founded in 1974 and is headquartered in Cleveland, Ohio.

Employees
226

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
7.37M12.89%43.65M
Other Institutional Investors
37.71M65.95%223.27M
Public Companies & Retail Investors
12.10M21.15%71.62M
Total
57.18M100.00%338.53M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Nantahala Capital Management, LLC8.98%5,136,49030,408
BlackRock, Inc.5.86%3,352,47419,847

People Also Watch

8.300
CRMD
-0.12%
11.565
ZVRA
-2.41%
2.1300
TENX
-2.74%
43.34
VCYT
-4.22%
68.42
FOXA
+1.79%

FAQ

What Is the Abeona Therapeutics (ABEO) Stock Price Today?

The Abeona Therapeutics stock price today is 5.9200 USD.

What Stock Exchange Does Abeona Therapeutics Trade On?

Abeona Therapeutics is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Abeona Therapeutics?

The stock symbol for Abeona Therapeutics is "ABEO."

What Is the Abeona Therapeutics Market Cap?

As of today, Abeona Therapeutics market cap is 338.5300M USD.

What Is Abeona Therapeutics's Earnings Per Share (TTM)?

The Abeona Therapeutics EPS (TTM) is -1.1840.

When Is the Next Abeona Therapeutics Earnings Date?

Abeona Therapeutics will release its next earnings report on Nov 16, 2026.

From a Technical Analysis Perspective, Is ABEO a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Abeona Therapeutics Stock Split?

Abeona Therapeutics has split 4 times.

How Many Employees Does Abeona Therapeutics Have?

Abeona Therapeutics has 226 employees.

What is the current trading status of Abeona Therapeutics (ABEO)?

As of Aug 30, 2026, Abeona Therapeutics (ABEO) is trading at a price of 5.9200 USD, with a previous close of 6.0400 USD. The stock has fluctuated within a day range of 5.8800 USD to 6.0350 USD, while its 52-week range spans from 4.0000 USD to 7.6500 USD.

What Is Abeona Therapeutics (ABEO) Price Target According to Analysts?

The average 12-month price target for Abeona Therapeutics is 18.8571 USD, with a high estimate of 28 USD and a low estimate of 14 USD. 6 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +218.53% Upside potential.

What Is the ABEO Premarket Price?

ABEO's last pre-market stock price is 6.1000 USD. The pre-market share volume is 750.0000, and the stock has decreased by 0.0600, or 0.9900%.

What Is the ABEO After Hours Price?

ABEO's last after hours stock price is 5.9700 USD, the stock has decreased by 0.0500, or 0.8400%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.